Javascript must be enabled to continue!
Recent Advancement in the Diagnosis and Treatment of Leprosy
View through CrossRef
Background:
Many of the tropical diseases are neglected by the researchers and medicinal
companies due to lack of profit and other interests. The Drugs for Neglected Diseases initiative (DNDi)
is established to overcome the problems associated with these neglected diseases. According to a report
published by the WHO, leprosy (Hansen's disease) is also a neglected infectious disease.
Methods:
A negligible amount of advancements has been made in last few decades which includes the
tools of diagnosis, causes, treatment, and genetic studies of the bacterium (Mycobacterium leprae) that
causes leprosy. The diagnosis of leprosy at earlier stages is important for its effective treatment. Recent
studies on vitamin D and its receptors make leprosy diagnosis easier at earlier stages. Skin biopsies and
qPCR are the other tools to identify the disease at its initial stages.
Results:
Until now a specific drug for the treatment of leprosy is not available, therefore, Multi-Drug
Therapy (MDT) is used, which is hazardous to health. Besides Mycobacterium leprae, recently a new
bacterium Mycobacterium lepromatosis was also identified as a cause of leprosy. During the last few
years the genetic studies of Mycobacterium leprae, the role of vitamin D and vitamin D receptors
(VDR), and the skin biopsies made the treatment and diagnosis of leprosy easier at early stages. The
studies of micro RNAs (miRNAs) made it easy to differentiate leprosy from other diseases especially
from tuberculosis.
Conclusion:
Leprosy can be distinguished from sarcoidosis by quantitative study of reticulin fibers present
in skin. The treatment used until now for leprosy is multi-drug treatment. The complete genome
identification of Mycobacterium leprae makes the research easy to develop target specified drugs for
leprosy. Rifampicin, identified as a potent drug, along with other drugs in uniform multi-drug treatment,
has a significant effect when given to leprosy patients at initial stages. These are effective treatments but
a specific drug for leprosy is still needed to be identified. The current review highlights the use of modern
methods for the identification of leprosy at its earlier stages and the effective use of drugs alone as
well as in combination.
Bentham Science Publishers Ltd.
Title: Recent Advancement in the Diagnosis and Treatment of Leprosy
Description:
Background:
Many of the tropical diseases are neglected by the researchers and medicinal
companies due to lack of profit and other interests.
The Drugs for Neglected Diseases initiative (DNDi)
is established to overcome the problems associated with these neglected diseases.
According to a report
published by the WHO, leprosy (Hansen's disease) is also a neglected infectious disease.
Methods:
A negligible amount of advancements has been made in last few decades which includes the
tools of diagnosis, causes, treatment, and genetic studies of the bacterium (Mycobacterium leprae) that
causes leprosy.
The diagnosis of leprosy at earlier stages is important for its effective treatment.
Recent
studies on vitamin D and its receptors make leprosy diagnosis easier at earlier stages.
Skin biopsies and
qPCR are the other tools to identify the disease at its initial stages.
Results:
Until now a specific drug for the treatment of leprosy is not available, therefore, Multi-Drug
Therapy (MDT) is used, which is hazardous to health.
Besides Mycobacterium leprae, recently a new
bacterium Mycobacterium lepromatosis was also identified as a cause of leprosy.
During the last few
years the genetic studies of Mycobacterium leprae, the role of vitamin D and vitamin D receptors
(VDR), and the skin biopsies made the treatment and diagnosis of leprosy easier at early stages.
The
studies of micro RNAs (miRNAs) made it easy to differentiate leprosy from other diseases especially
from tuberculosis.
Conclusion:
Leprosy can be distinguished from sarcoidosis by quantitative study of reticulin fibers present
in skin.
The treatment used until now for leprosy is multi-drug treatment.
The complete genome
identification of Mycobacterium leprae makes the research easy to develop target specified drugs for
leprosy.
Rifampicin, identified as a potent drug, along with other drugs in uniform multi-drug treatment,
has a significant effect when given to leprosy patients at initial stages.
These are effective treatments but
a specific drug for leprosy is still needed to be identified.
The current review highlights the use of modern
methods for the identification of leprosy at its earlier stages and the effective use of drugs alone as
well as in combination.
Related Results
Knowledge and self-care practice of leprosy patients at ALERT Hospital,
Ethiopia
Knowledge and self-care practice of leprosy patients at ALERT Hospital,
Ethiopia
Abstract
Background
Leprosy is a chronic infectious disease of public health importance and
one of ...
EVALUATION OF HISTOPATHOLOGICAL EXAMINATION OF SKIN BIOPSY IN DIAGNOSIS OF LEPROSY WITH CLINICAL CORRELATION
EVALUATION OF HISTOPATHOLOGICAL EXAMINATION OF SKIN BIOPSY IN DIAGNOSIS OF LEPROSY WITH CLINICAL CORRELATION
Background: Leprosy is a chronic granulomatous infection caused by M. leprae (also known as Hansen disease) predominantly affects the skin
and peripheral nerves. It is difcult to ...
Epidemiological Characteristics and Factors Associated with Cure of Leprosy in Chongqing, China, from 1949 to 2019
Epidemiological Characteristics and Factors Associated with Cure of Leprosy in Chongqing, China, from 1949 to 2019
ABSTRACT.
Chongqing is one of the focuses of leprosy control in China. Although leprosy control in Chongqing has achieved remarkable results over the years, there are also some pro...
Prevalence of HIV in Leprosy Patients in Central Myanmar during 2008
Prevalence of HIV in Leprosy Patients in Central Myanmar during 2008
HIV infection has been shown to be strongly associated with the development of active tuberculosis. However, its association with leprosy was much less clear. Moreover, seroprevale...
Borderline Lepromatous Leprosy with Severe Erythema Nodosum Leprosum: A Case Report
Borderline Lepromatous Leprosy with Severe Erythema Nodosum Leprosum: A Case Report
Background: Leprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae (M. leprae) that primarily infects Schwann cells in the peripheral nerves, leading ...
The Relationship of the Level of Knowledge About Leprosy and Self Care Agency in Leper Patients at The Leper Poly, Daha Husada Hospital, Kediri
The Relationship of the Level of Knowledge About Leprosy and Self Care Agency in Leper Patients at The Leper Poly, Daha Husada Hospital, Kediri
Leprosy (Leprosy) is a chronic infectious disease caused by Mycobacterium leprae. This disease primarily affects the skin, peripheral nerves, and eyes. The purpose of the study was...
Morbus hansen tipe borderline lepromatous pada seorang anak dengan riwayat narakontak erat kusta tipe mulibasiler: laporan kasus
Morbus hansen tipe borderline lepromatous pada seorang anak dengan riwayat narakontak erat kusta tipe mulibasiler: laporan kasus
Background: Leprosy is a chronic granulomatous disease caused by Mycobacterium leprae and Mycobaterium lepromatosis. Children are one of the populations at risk of M. leprae transm...
Interaction between leprosy and HIV infection
Interaction between leprosy and HIV infection
Introduction: Leprosy and Human Immunodeficiency Virus (HIV) infections still count as major health issues worldwide. Starting with the HIV pandemic back in the eighties, leprosy w...

